Estudios inmunohematológicos en pacientes sometidos a transplante alogénico de médula ósea

Zani, Néstor Alberto.
Hemotecnica ; 5(2): 14-9, jul. 1995. tab
Artículo en Español | LILACS | ID: lil-251383

Documentos relacionados

  1. Response to Haspel and McKenna 'Major incompatible red blood cell transfusions prior to bone marrow transplantation: Not worth the risk'.
  2. The devil is in the details: retention of recipient group A type 5 years after a successful allogeneic bone marrow transplant from a group O donor.
  3. Improving the safety of tolerance induction: chimerism and cellular co-treatment strategies applied to vascularized composite allografts.
  4. Major incompatible red blood cell transfusions prior to bone marrow transplantation: Not worth the risk.
  5. Acceptable HLA-mismatching in unrelated donor bone marrow transplantation for patients with acquired severe aplastic anemia.
  6. Past and future of providing matched, unrelated donors for marrow transplantation.
  7. Relevance of 10 Caucasian HLA haplotypes in searches for unrelated bone marrow donors for 100 patients from a single center.
  8. Transplantation of ABO-incompatible bone marrow and peripheral blood stem cell components.
  9. American Society of Blood and Marrow Transplantation Guidelines for Training in Hematopoietic Progenitor Cell Transplantation.
  10. Bone marrow harvest in donors with anaemia.